Skip to main content

Table 1 Clinical characteristics at cross-sectional visit of patients in MTX and biologic era cohorts

From: Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era

 

MTX era (n = 239)

Biologic era (n = 269)

P

Female

189 (79.1)

219 (81.4)

0.51

Median (IQR) age at disease onset, years

3.1 (1.8–5.8)

2.5 (1.6–4.7)

0.016

Median (IQR) disease duration at study visit, years

7.7 (6.1–10.2)

6.9 (5.4–9.7)

0.0005

Median (IQR) disease duration at first observation, years

0.7 (0.2–2.0)

0.6 (0.2–1.8)

0.52

ILAR category

 Systemic arthritis

23 (9.6)

17 (6.3)

0.0025

 RF-negative polyarthritis

49 (20.5)

51 (19.0)

 RF-positive polyarthritis

5 (2.1)

0.0 (0.0)

 Persistent oligoarthritis

73 (30.5)

119 (44.2)

 Extended oligoarthritis

55 (23.0)

63 (23.4)

 Psoriatic arthritis

15 (6.3)

7 (2.6)

 Undifferentiated arthritis

19 (7.9)

12 (4.5)

 Patients with positive ANA

184 (77.0)

221 (82.2)

0.05

Past treatment

 Methotrexate

153 (64.0)

209 (77.7)

0.0007

 Cyclosporin A

58 (24.3)

19 (7.0)

< 0.0001

 Sulfasalazine

17 (7.1)

7 (2.6)

0.017

 Biologic DMARDs

26 (10.9)

99 (36.8)

< 0.0001

 Etanercept

23 (9.6)

84 (31.2)

< 0.0001

 Infliximab

5 (2.1)

4 (1.5)

0.74

 Adalimumab

27 (10.0)

 Anakinra

7 (2.6)

 Abatacept

3 (1.1)

 Tocilizumab

4 (1.5)

 Systemic glucocorticoids

92 (38.5)

85 (31.6)

0.10

 Intraarticular glucocorticoids

187 (78.2)

250 (93.0)

< 0.0001

Present treatment

 Methotrexate

90/200 (45.0)

95/266 (35.7)

0.043

 Cyclosporin A

18/200 (9.0)

3/266 (1.1)

< 0.0001

 Biologic DMARDs

16/200 (8.0)

89/266 (33.5)

< 0.0001

 Systemic glucocorticoids

8/200 (4.0)

8/266 (3.0)

0.56

 No therapy

52/200 (26.0)

90/266 (33.8)

0.069

  1. Data are number positive/number with information available (percentage) unless otherwise indicated; reference [11]
  2. MTX methotrexate, IQR interquartile range, RF rheumatoid factor, ANA antinuclear antibodies, DMARDs disease antirheumatic drugs